CIRCULATING TUMOUR CELLS
An evidence-aware overview of CTC analysis and its limitations in medical decision-making.
CTCs are tumour-derived cells shed into the bloodstream from a primary or metastatic site. Detection and enumeration are used in research and selected clinical contexts, but a CTC result alone cannot establish whether cancer is present, where it began or whether it has recurred.
ABOUT THE INFORMATION
CTC research findings and the information available from an individual test should be considered separately.
CURRENT POSITION
CTCs are studied as a form of liquid biopsy, including associations with prognosis in some advanced cancers. Important gaps remain for population screening, method standardisation and proof that CTC-directed treatment changes improve outcomes.
PROCESS
LIMITATIONS
PUBLICATION
A pilot study of a microfluidic device in gynaecologic cancer is presented as background material for CTC research. Its applicability depends on the population, method and intended use.
FAQ
Current evidence does not support treating CTC analysis as a stand-alone general cancer screening test. Use age- and risk-appropriate standard screening.
No. CTCs are rare and detection depends on sampling and method. A non-detected result cannot exclude cancer.
CONSULTATION
Confirm the platform, intended use, cost, report format and clinical responsibilities before considering implementation.
